Radiology, Vol 137, 217-222, Copyright © 1980 by Radiological Society of North America
Clinical trials with a new intravenous liposoluble contrast material for computed tomography of the liver and spleen
M Vermess, JL Doppman, P Sugarbaker, RI Fisher, DC Chatterji, J Luetzeler, G Grimes, M Girton and RH Adamson
Ten patients with disseminated cancer were given intravenous injections of
0.2 ml/kg (40 mg l/kg) of the experimental contrast material EOE 13. Ct
scans of the liver and spleen were taken prior to and 30 minutes after
contrast infusion. Visualization of the liver was significantly improved in
5, moderately improved in 3, and not appreciably improved in 2. The spleen
showed an obvious increase in density in all cases. No significant toxicity
was encountered: untoward side effects consisted of fever, headaches, foul
metallic taste, and weakness for a short period. Four patients had no side
effects, and 2 experienced only abnormal taste sensation. Further
experimental and clinical work is needed before the advantages and safety
of this contrast material can be documented.
